Sun Pharmaceutical Industries has signed a licensing deal with Swiss-Italian firm Philogen to commercialise anti-cancer biopharmaceutical in Europe, Australia and New Zealand.

What Happened? Under the deal, Sun Pharma will have exclusive rights to commercialise Nidlegy, which has applications in treating skin cancers, in the three territories.

Philogen will conduct clinical trials for the product in Europe, seek regulatory approval for marketing, and handle manufacturing of commercial supplies, while Sun Pharma will take charge of commercialization efforts.

See Also: JioCinema Hits Record-Breaking 3.3 Cr Concurrent IPL Viewers During Final

The firms will split their earnings from the commercialisation equally between them. Philogen will retain the intellectual property rights for the treatment in other territories and for applications other than for skin cancer.

“With the expected addition of Nidlegy to our existing Odomzo franchise, we will be well-positioned to provide patient solutions across a broad spectrum of skin cancers in various disease stages,” said Hellen De Kloet, Sun Pharmaceutical’s business head for Western Europe and Australia and New Zealand.

Read Next: Looking To Save More? HDFC Bank Offers Higher FD Rates For Limited Time